BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The business model for Fortress Biotech Inc....
...with the donor template (see “Trucode: Advancing Nuclease-Free, Viral Vector-Independent Gene Therapy” ). Lauren Martz, Senior Editor Fortress Biotech Inc. Columbia...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...Complexa Inc. hired Elisabeth Leiderman as CBO. She was SVP, head of corporate development for Fortress Biotech Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...for $240 million in milestones, plus royalties. Fortress’ Baergic partners with AZ for CNS disorders Fortress Biotech Inc....
...GCPII) - Prostate-specific membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Inc. (NASDAQ:RTRX) Fosmetpantotenate Treat pantothenate kinase-associated neurodegeneration (PKAN) Phase III data 3Q19 Revogenex Inc. / Fortress Biotech Inc....
BioCentury | Apr 17, 2019
Clinical News

St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

...age two, and eight patients have so far received treatment. Mustang is a subsidiary of Fortress Biotech Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Inc. (NASDAQ:RVNC) DaxibotulinumtoxinA Treat moderate to severe glabellar lines Submit BLA 2Q19 Revogenex Inc. / Fortress Biotech Inc....
BioCentury | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

...amyloidosis. The deal gives Alexion a path to gain rights to CAEL-101, Caelum's sole asset. Fortress Biotech Inc....
...said the measure was "not studied or published by Prothena." Paul Bonanos 11-1F4, CAEL-101 Alexion Pharmaceuticals Inc. Caelum Biosciences Inc. Fortress Biotech Inc....
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...cancer Ph I Interleukin-13 receptor α 2 (IL-13RA2; IL-13R; CD213A2) Mustang Bio Inc. (NASDAQ:MBIO) / Fortress Biotech Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...AZD5153 in Phase I testing for solid tumors. Jubilant Life Sciences Ltd., Checkpoint Therapeutics Inc., Fortress Biotech Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Inflammation

...AZD5153 in Phase I testing for solid tumors. Jubilant Life Sciences Ltd., Checkpoint Therapeutics Inc., Fortress Biotech Inc....
Items per page:
1 - 10 of 130
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The business model for Fortress Biotech Inc....
...with the donor template (see “Trucode: Advancing Nuclease-Free, Viral Vector-Independent Gene Therapy” ). Lauren Martz, Senior Editor Fortress Biotech Inc. Columbia...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...Complexa Inc. hired Elisabeth Leiderman as CBO. She was SVP, head of corporate development for Fortress Biotech Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...for $240 million in milestones, plus royalties. Fortress’ Baergic partners with AZ for CNS disorders Fortress Biotech Inc....
...GCPII) - Prostate-specific membrane antigen Hongjiang Li, Staff Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Inc. (NASDAQ:RTRX) Fosmetpantotenate Treat pantothenate kinase-associated neurodegeneration (PKAN) Phase III data 3Q19 Revogenex Inc. / Fortress Biotech Inc....
BioCentury | Apr 17, 2019
Clinical News

St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

...age two, and eight patients have so far received treatment. Mustang is a subsidiary of Fortress Biotech Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...Inc. (NASDAQ:RVNC) DaxibotulinumtoxinA Treat moderate to severe glabellar lines Submit BLA 2Q19 Revogenex Inc. / Fortress Biotech Inc....
BioCentury | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

...amyloidosis. The deal gives Alexion a path to gain rights to CAEL-101, Caelum's sole asset. Fortress Biotech Inc....
...said the measure was "not studied or published by Prothena." Paul Bonanos 11-1F4, CAEL-101 Alexion Pharmaceuticals Inc. Caelum Biosciences Inc. Fortress Biotech Inc....
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...cancer Ph I Interleukin-13 receptor α 2 (IL-13RA2; IL-13R; CD213A2) Mustang Bio Inc. (NASDAQ:MBIO) / Fortress Biotech Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...AZD5153 in Phase I testing for solid tumors. Jubilant Life Sciences Ltd., Checkpoint Therapeutics Inc., Fortress Biotech Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Inflammation

...AZD5153 in Phase I testing for solid tumors. Jubilant Life Sciences Ltd., Checkpoint Therapeutics Inc., Fortress Biotech Inc....
Items per page:
1 - 10 of 130